Seven US Democratic Senators are reportedly calling or regulators to review the proposed acquisition of Allergan, which makes Botox, by Canada’s Valeant Pharmaceuticals.
According to reports, lawmakers want the $54 billion hostile takeover offer reviewed, citing former Valeant buyouts that lead to job cuts.
The company reportedly cut hundreds of jobs in New York after buying Bausch + Lomb.
Allergan twice has rejected Valeant’s buyout offers, claiming they severely undervalue the US pharmaceutical company. Valeant then joined Allergan shareholder Pershing Square Capital Management for the latest bid in efforts to oust the board of directors to secure the acquisition deal.
Full content: Democrat and Chronicle
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI